Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL7013 nasal spray in non-hospitalized patients with COVID-19
ISRCTN70449927Phase 4Completed
- Sponsor
- Starpharma
- Start
- Dec 2022
- Modality
- Peptides, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing SPL7013 nasal spray with Placebo saline nasal spray (2 arms). Primary endpoint: Area under the curve of nasal swab SARS-CoV-2 viral load through Day 7. Started Dec 2022; status: completed.
02
Drugs
astodrimer
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN70449927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70449927.